Minerva Neurosciences | NERV - Capital De Empréstimo





Capital De Empréstimo Alterar Data
Acadia Pharmaceuticals USD 0 0 2025-03
Adma Biologics USD 69.33M 750K 2025-12
ALKERMES USD 285.82M 639K 2024-09
Alterity Therapeutics Limited AUD 43.68K 59.53K 2025-12
AstraZeneca USD 25.96B 177M 2026-03
BioCryst Pharmaceuticals USD 428.67M 234.31M 2025-12
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Cipla INR 2.98B 454.6M 2025-09
Clal Biotechnology ILS 25.96M 18.48M 2023-12
Compugen USD 0 0 2024-12
CSL USD 10.42B 273M 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
Esperion Therapeutics USD 457.65M 9.5M 2025-12
GlaxoSmithKline GBP 14.01B 696M 2026-03
Grifols EUR 9.95B 722.93M 2025-12
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
J&J USD 37.53B 1.91B 2026-03
Merck USD 46.67B 77M 2026-03
Minerva Neurosciences USD 0 86.58M 2024-09
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.45B 7.86B 2026-03
Novavax USD 246.3M 200K 2025-12
Pfizer USD 60.57B 1.08B 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sanofi EUR 13.84B 1.88B 2026-03
Takeda JPY 4.27T 81.29B 2025-12
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12